Posts tagged ‘drugs’
New Government Report: Potential Effects of a Ban on Direct-to-Consumer Advertising of New Prescription Drugs
by Sheila Campbell
Paperback, 8 pages, 2011, $10.00
Concerns about direct-to-consumer advertising of prescription drugs have spurred recent proposals for a moratorium on advertising brand-name prescription drugs to consumers during the first two years following a drug’s approval by the Food and Drug Administration. This report examines some of the effects of such a moratorium, drawing on data documenting direct-to-consumer advertising and other promotional activities used by pharmaceutical producers as well as academic analyses of how advertising has affected the market for drugs. Charts and tables. This is a print on demand edition of an important, hard-to-find publication.
by John E. Dicken
Paperback, 28 pages, 2011, $20.00
Prescription drug spending in the U.S. in 2009 totaled $250 billion, of which $78 billion — or 31% — was spent by the federal government. Prescription drug spending by the federal government, patients, and third-party payers, including employers, is driven by many factors, including the prices paid for drugs. This report: (1) examines usual and customary price trends for commonly used prescription drugs from 2006 through the first quarter of 2010 and compares these trends to those of other medical consumer goods and services; and (2) examines price trends using drug prices other than usual and customary. Also provides information on the extent to which prices for individual brand-name drugs changed over the course of this analysis period. Charts and tables.
New Drug Approval: FDA’s Consideration of Evidence from Certain Clinical Trials
by Marcia Crosse
Paperback, 38 pages, 2010, $30.00
“Before approving a new drug, the FDA assesses a drug’s effectiveness. To do so, it examines information contained in a new drug application (NDA), including data from clinical trials in humans. Several types of trials may be used to gather this evidence. Non-inferiority trials aim to demonstrate that the difference between the effectiveness of a new drug and an active control is small enough to show that the new drug is also effective. FDA has issued guidance on these trials. This report: (1) identifies NDAs for new molecular entities — potentially innovative new drugs not FDA-approved in any form — that included evidence from non-inferiority trials; (2) examines the characteristics of these trials; and (3) describes FDA’s guidance on these trials.”
New Government Report: New Jersey Syringe Access Program Demonstration Project Interim Report: Implementation of P.L. 23006, c.99, Blood-borne Disease Harm Reduction Act
New Jersey Syringe Access Program Demonstration Project Interim Report: Implementation of P.L. 23006, c.99, Blood-borne Disease Harm Reduction Act
by Laurence E. Ganges
Paperback, 17 pages, 2010, ISBN: 9781437935059, $15.00
Four years ago, New Jersey became the last state to approve needle-exchange programs to curb the spread of HIV/AIDS by drug addicts, reports the Philadelphia Inquirer. A new state Health Department report shows those efforts are making a difference, and offers evidence that the pilot programs should continue. But they are threatened by a lack of funding.
Injection drug use is one of the most common methods of transmission for a number of preventable life‐threatening diseases, including HIV and Hepatitis C.
Along with drug treatment and behavioral health interventions, syringe access programs are an important component in attempting to prevent/reduce the risks associated with injection drug use.
On Dec. 19, 2006, Governor Corzine signed the “Blood‐borne Disease Harm Reduction Act,” which allows a maximum of six municipalities in NJ to establish a demonstration syringe access program.
This report presents an evaluation of the Demonstration Project based on data collected from the inception of the first site from Nov. 27, 2007 through Dec. 31, 2009. Charts and tables.
New Government Report: Pharmaceutical R&D and the Evolving Market for Prescription Drugs (ISBN: 1437925057)
Pharmaceutical R&D and the Evolving Market for Prescription Drugs (ISBN: 1437925057)
By David Austen and Colia Baker
(Paperback, 8 pages, 2009, $10.00)
Investment in Research and Development (R&D) over the past several decades has produced a wealth of valuable new drug therapies that have made it possible to treat major illnesses that were not treated previously or were not treated as effectively.
As the scope of available drug therapies expanded, spending on prescription drugs became the fastest-growing category of total spending on health care in the U.S. Between 1994 and 2004, real (inflation-adjusted) spending on prescription drugs rose at an average annual rate of 11.1%, compared with 3.5% for hospital care and 4.3% for physicians’ services.
More recently, however, that growth has slowed: From 2004 to 2007, drug expenditures grew by an average of just 3.2% per year, slightly less than the rate of growth in overall health care spending. As a fraction of total spending on health care, spending on prescription drugs rose from 6% in 1994 to around 11% in 2004, where it has remained.
That slowdown in the rate of growth in spending reflects changes in both the supply of and the demand for prescription drugs. The greater the expected revenue from a prospective new drug, the more willing a drugmaker will be to invest to develop it. Those decisions will help determine which drug therapies become available in the future and thus will affect future growth in health care costs.
This report describes the current state of investment in drug R&D and the factors that influence it. It also examines how various policy options to control the growth in health care costs or to expand insurance coverage could affect R&D spending. Figures.
New Government Report: Treaties Latin America and the Caribbean: Illicit Drug Trafﬁcking and U.S. Counterdrug (ISBN: 1437934056)
Treaties Latin America and the Caribbean: Illicit Drug Trafﬁcking and U.S. Counterdrug (ISBN: 1437934056)
By Clare Ribando Seelke
(Paperback, 34 pages, 2010, $20)
Earlier in June 2010, Secretary of State Hillary Clinton toured Latin America and the Caribbean to discuss issues, including drug trafficking, Politics Daily reported. On the agenda were the lawless border regions — between, for one, Colombia and Ecuador — where legitimate governments are stymied by non-state actors wielding sub-machine guns and running drugs. The Washington Office on Latin America noted that drug money from Venezuela and other countries is funneled throughout the Caribbean, corrupting officials and paving the way for safe passage of drugs.
Contents: (1) An Overview of Illicit Drugs in Latin America and the Caribbean: Drug Traffickers and Related Criminal-Terrorist Actors; (2) U.S. Antidrug Assistance Programs in Latin America: Plan Colombia: Mérida Initiative for Mexico and Central America: U.S. Assistance to Mexico Beyond Mérida; Central American Regional Security Initiative; Caribbean Basin Security Initiative; Department of Defense (DoD) Counternarcotics Assistance Programs; (3) Foreign Assistance Prohibitions and Conditions: Annual Drug Certification Process; Conditions on Counternarcotics Assistance: Human Rights Prohibitions on Assistance to Security Forces; Country-Specific Prohibitions on Certain Counterdrug Assistance; Drug Eradication-Related Conditions; (4) Issues for Congress. Illustrations.
New Government Report: Extradition To and From the United States: Overview of the Law and Recent (ISBN: 1437934811)
Extradition To and From the United States: Overview of the Law and Recent (ISBN: 1437934811)
By Michael John Garcia and Charles Doyle
(Paperback, 44 pages, 2010, $20)
In May 2010, after years of opposition and recent pressure from the Obama administration, Jamaican Prime Minister Bruce Golding last week reversed his stance and okayed the extradition of alleged drug king pin Christopher (Dudus) Coke to stand trial in New York, reports the New York Daily News. Today, Coke was captured, reports the Christian Science Monitor.
“Extradition” is the formal surrender of a person by a State to another State for prosecution or punishment. The U.S. has extradition treaties with over a hundred nations, although there are many countries with which it has no extradition treaty. International terrorism and drug trafficking have made extradition an increasingly important law enforcement tool.
Contents of this report: (1) Intro.; (2) Bars to Extradition; (3) Constitutionality; (4) Procedure for Extradition from the U.S.: Arrest and Bail; Hearing; Review; Surrender; (5) Extradition for Trial or Punishment in the U.S.; (6) Alternatives to Extradition; Waiver. Append.: Countries with Which the U.S. Has a Bilateral Extradition Treaty, and those with Which the U.S. Has No Bilateral Extradition Treaty.